Zobrazeno 1 - 10
of 597
pro vyhledávání: '"Ladan, Fazli"'
Autor:
Xia Sheng, Hatice Zeynep Nenseth, Su Qu, Omer F. Kuzu, Turid Frahnow, Lukas Simon, Stephanie Greene, Qingping Zeng, Ladan Fazli, Paul S. Rennie, Ian G. Mills, Håvard Danielsen, Fabian Theis, John B. Patterson, Yang Jin, Fahri Saatcioglu
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-3 (2024)
Externí odkaz:
https://doaj.org/article/3fde716d893d4f1e9d0bb5dad157a6f5
Autor:
Roosa Kaarijärvi, Heidi Kaljunen, Lucia Nappi, Ladan Fazli, Sonia H. Y. Kung, Jaana M. Hartikainen, Ville Paakinaho, Janne Capra, Kirsi Rilla, Marjo Malinen, Petri I. Mäkinen, Seppo Ylä-Herttuala, Amina Zoubeidi, Yuzhuo Wang, Martin E. Gleave, Mikko Hiltunen, Kirsi Ketola
Publikováno v:
Communications Biology, Vol 7, Iss 1, Pp 1-13 (2024)
Abstract Treatment-induced neuroendocrine prostate cancer (t-NEPC) is a lethal subtype of castration-resistant prostate cancer resistant to androgen receptor (AR) inhibitors. Our study unveils that AR suppresses the neuronal development protein dihyd
Externí odkaz:
https://doaj.org/article/46ae70a2bbdb4b58945c409e3ad0a352
Autor:
Iryna Saranchova, Clara Wenjing Xia, Stephanie Besoiu, Pablo L. Finkel, Samantha L. S. Ellis, Suresh Kari, Lonna Munro, Cheryl G. Pfeifer, Ladan Fazli, Martin E. Gleave, Wilfred A. Jefferies
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Cell-based cancer immunotherapy has achieved significant advancements, providing a source of hope for cancer patients. Notwithstanding the considerable progress in cell-based immunotherapy, the persistently low response rates and the exorbitant costs
Externí odkaz:
https://doaj.org/article/84770b6c7e8544bcacd0fa5532f52bcb
Autor:
Takuya Tsujino, Tomoaki Takai, Kunihiko Hinohara, Fu Gui, Takeshi Tsutsumi, Xiao Bai, Chenkui Miao, Chao Feng, Bin Gui, Zsofia Sztupinszki, Antoine Simoneau, Ning Xie, Ladan Fazli, Xuesen Dong, Haruhito Azuma, Atish D. Choudhury, Kent W. Mouw, Zoltan Szallasi, Lee Zou, Adam S. Kibel, Li Jia
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-19 (2023)
Identifying prostate cancer patients who may respond well to PARP inhibitors is important for their success in the clinic. Here, using a genome-wide CRISPR-Cas9 knockout screen, the authors identify MMS22L as a biomarker for sensitivity to PARP inhib
Externí odkaz:
https://doaj.org/article/ae5f553e58e5416b821643fde0923364
Autor:
Nader Al-Nakouzi, Chris Kedong Wang, Htoo Zarni Oo, Irina Nelepcu, Nada Lallous, Charlotte B. Spliid, Nastaran Khazamipour, Joey Lo, Sarah Truong, Colin Collins, Desmond Hui, Shaghayegh Esfandnia, Hans Adomat, Thomas Mandel Clausen, Tobias Gustavsson, Swati Choudhary, Robert Dagil, Eva Corey, Yuzhuo Wang, Anne Chauchereau, Ladan Fazli, Jeffrey D. Esko, Ali Salanti, Peter S. Nelson, Martin E. Gleave, Mads Daugaard
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-14 (2022)
Chondroitin sulfate (CS) is one of the most abundant glycosaminoglycans in prostate cancers. Here the authors show that inhibition of the androgen receptor pathway leads to the upregulation of CS, which promotes prostate cancer growth and metastasis.
Externí odkaz:
https://doaj.org/article/22e286a19f144d4daece67eee9f8ec9e
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-11 (2022)
Abstract Protein glycosylation, the attachment of carbohydrates onto proteins, is a fundamental process that alters the biological activity of proteins. Changes to glycosylation states are associated with many forms of cancer including breast cancer.
Externí odkaz:
https://doaj.org/article/cb23195f89574b36b7e544d22c1a6ce2
Autor:
Arnaud Blomme, Coralie Peter, Ernest Mui, Giovanny Rodriguez Blanco, Ning An, Louise M Mason, Lauren E Jamieson, Grace H McGregor, Sergio Lilla, Chara Ntala, Rachana Patel, Marc Thiry, Sonia H Y Kung, Marine Leclercq, Catriona A Ford, Linda K Rushworth, David J McGarry, Susan Mason, Peter Repiscak, Colin Nixon, Mark J Salji, Elke Markert, Gillian M MacKay, Jurre J Kamphorst, Duncan Graham, Karen Faulds, Ladan Fazli, Martin E Gleave, Edward Avezov, Joanne Edwards, Huabing Yin, David Sumpton, Karen Blyth, Pierre Close, Daniel J Murphy, Sara Zanivan, Hing Y Leung
Publikováno v:
EMBO Molecular Medicine, Vol 14, Iss 3, Pp 1-21 (2022)
Abstract Despite the clinical benefit of androgen‐deprivation therapy (ADT), the majority of patients with advanced prostate cancer (PCa) ultimately develop lethal castration‐resistant prostate cancer (CRPC). In this study, we identified thioeste
Externí odkaz:
https://doaj.org/article/0b32d6de175042e18b789240104f3924
Autor:
Zheng Wang, Mohit Hulsurkar, Lijuan Zhuo, Jinbang Xu, Han Yang, Samira Naderinezhad, Lin Wang, Guoliang Zhang, Nanping Ai, Linna Li, Jeffrey T. Chang, Songlin Zhang, Ladan Fazli, Chad J. Creighton, Fang Bai, Michael M. Ittmann, Martin E. Gleave, Wenliang Li
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 23, Iss 11, Pp 1147-1165 (2021)
Epithelial-mesenchymal transition (EMT) contributes to tumor invasion, metastasis and drug resistance. AKT activation is key in a number of cellular processes. While many positive regulators for either EMT or AKT activation have been reported, few ne
Externí odkaz:
https://doaj.org/article/8c48a73040db41e99238a7ba9fbf044c
Autor:
Neetu Saxena, Eliana Beraldi, Ladan Fazli, Syam Prakash Somasekharan, Hans Adomat, Fan Zhang, Chidi Molokwu, Anna Gleave, Lucia Nappi, Kimberly Nguyen, Pavn Brar, Nicholas Nikesitch, Yuzhuo Wang, Colin Collins, Poul H Sorensen, Martin Gleave
Publikováno v:
EMBO Molecular Medicine, Vol 13, Iss 5, Pp 1-19 (2021)
Abstract Treatment‐induced adaptive pathways converge to support androgen receptor (AR) reactivation and emergence of castration‐resistant prostate cancer (PCa) after AR pathway inhibition (ARPI). We set out to explore poorly defined acute adapti
Externí odkaz:
https://doaj.org/article/5793efb5d6f840efadd0ab2793d10dfc
Autor:
Yundong He, Ting Wei, Zhenqing Ye, Jacob J. Orme, Dong Lin, Haoyue Sheng, Ladan Fazli, R. Jeffrey Karnes, Rafael Jimenez, Liguo Wang, Liewei Wang, Martin E. Gleave, Yuzhuo Wang, Lei Shi, Haojie Huang
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-14 (2021)
Resistance to second generation anti-androgen therapies such as enzalutamide (ENZ) can emerge in prostate cancer patients. Here, the authors identify an ENZ-resistant mechanism driven by AR-dependent transcription of noncanonical targets that make re
Externí odkaz:
https://doaj.org/article/00b4af7118804738bdce75145ea247c5